Pharmaceuticals, Biotechnology and Life Sciences
Field reps can compliantly create sample orders and fulfill requests from healthcare professionals during remote meetings Rapid pace of Veeva…
PrecisionLife is extending its relationships with some of the largest COVID-19 collaborative research projects as it offers free use of its analytics platform and support from its data and biomedical science teams in the fight against COVID19 coronavirus.
Hemogenyx Pharmaceuticals got European Patent Office’s patent entitled Post-Natal Hemogenic Endothelial Cells and their isolation and use.
Applied DNA Sciences has signed an Agreement with Stony Brook University Hospital (the “Hospital”) to validate and implement the Company’s patent-pending nucleic acid diagnostic (LineaCOVID-19™) to detect and quantify in diagnostic samples the presence of SARS-CoV-2, the virus that causes the disease, COVID-19.
Roche said Monday that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and the European Medicines Agency (EMA) has validated the application for a two-hour OCREVUS® (ocrelizumab) infusion time, dosed twice yearly for relapsing or primary progressive multiple sclerosis (MS).
Sanofi and GSK today announced teaming up to work on a vaccine for COVID-19, as Sanofi will contribute its S-protein COVID-19 antigen, and GSK contributing pandemic adjuvant technology.
BIOGGIO, Switzerland–(BUSINESS WIRE)–The KD Pharma Group (“KD Pharma”) and its partner, SLA Pharma (“SLA”), announced that its new drug candidate…
Tiziana Life Sciences said Thursday it has developed investigational new technology to treat COVID-19 infections.
Dynavax Technologies Corporation said Wednesday it is donating 10,000 doses of HEPLISAV-B adult vaccine to help protect healthcare professionals on the front lines of the COVID-19 response against hepatitis B.
GlaxoSmithKline and Vir Biotechnology have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19, in which GSK will make an equity investment in Vir of $250 million, to gain access to Vir’s technology.